Gilead Sciences, Inc.
) recently presented encouraging data on its chronic angina drug
Ranexa (ranolazine) from a phase IV study (TERISA: n=927). The
TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects with
Chronic Stable Angina) evaluated the efficacy of drug (as a
combination therapy) in chronic stable angina patients with
concurrent type II diabetes. Angina refers to a type of chest
pain that occurs due to lack of oxygen supply to the heart.
Gilead presented the data at the 62nd annual scientific session
of the American College of Cardiology.
ARRAY BIOPHARMA (ARRY): Free Stock Analysis
CELLDEX THERAPT (CLDX): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
KYTHERA BIOPHRM (KYTH): Free Stock Analysis
To read this article on Zacks.com click here.
The patients evaluated in the randomized, double-blind,
placebo-controlled, parallel study remained symptomatic for
angina even after being treated with a stable dose of one or two
concomitant antianginal agents.
Results from the study revealed that type II diabetes patients
treated with Ranexa experienced a significant reduction in weekly
episodes of chronic angina compared to those in the placebo.
Gilead stated in its press release that angina results from
exertion or emotional stress. GILD further stated that
diabetes patients have more extensive coronary artery disease and
a propensity for greater angina burden as opposed to non-
Gilead is evaluating Ranexa in multiple studies apart from TERISA
in patients with chronic angina and/or type II diabetes. Ranexa
has performed well in phase II studies in patients with chronic
angina and/or type II diabetes. Top-line results from 3 phase III
studies for the new indication are expected by the end of the
year. We note that 2012 sales of Ranexa, which is marketed for
the chronic angina indication, climbed 17% to $372.9 million. If
Ranexa is approved for treating patients with chronic angina
and/or type II diabetes then the sales potential of the drug
would be boosted.
Gilead, a biopharmaceutical company, currently carries a Zacks
Rank #3 (Hold). Biopharma stocks such as
Celldex Therapeutics, Inc.
Kythera Biopharmaceuticals, Inc.
) are comparatively well placed and carry a Zacks Rank #2